{"id":1288655,"date":"2020-03-27T14:14:14","date_gmt":"2020-03-27T18:14:14","guid":{"rendered":"https:\/\/xy-yishc.shop\/?p=1288655"},"modified":"2020-03-27T14:18:25","modified_gmt":"2020-03-27T18:18:25","slug":"minnesota-launches-trial-for-potential-covid-19-treatment-btn-livebig","status":"publish","type":"post","link":"https:\/\/xy-yishc.shop\/2020\/03\/27\/minnesota-launches-trial-for-potential-covid-19-treatment-btn-livebig\/","title":{"rendered":"Minnesota launches trial for potential COVID-19 treatment: BTN LiveBIG"},"content":{"rendered":"\n
For good and ill, the antimalarial drug hydroxychloroquine has been thrust into the national spotlight in recent weeks. It?s possible utility in treating COVID-19 has inspired reactions ranging from cautious hope to wild speculation, occasionally from the highest levels.<\/p>\n
What is clear, though, is the need to test hydroxychloroquine?s efficacy in disabling the coronavirus in humans. To that end, the University of Minnesota<\/a> Medical School recently launched the first national human trials.<\/p>\n Daniel Boulware, MD, MPH, a professor of Medicine in the Division of Infectious Diseases, helms the trial, along with an interdisciplinary team including infectious disease faculty physicians, biostatisticians, pharmacologists and students.<\/p>\n ?If effective, this may become a worldwide standard of care for helping prevent disease in other healthcare workers and people exposed,? Boulware said in a press release. ?Hydroxychloroquine is an off-patent, generic medicine that is inexpensive. A five-day treatment course would cost approximately $12.?<\/p>\n Open to those knowingly exposed to COVID-19 in a household setting and exposed healthcare workers, the blind study investigates treatment activity in 1,500 subjects. The trial targets only those with high-risk exposure in order to expedite results. Researchers will dose half of the subjects with hydroxychloroquine, the rest with an inert vitamin tablet.<\/p>\n The effort to find a treatment for COVID-19 is of paramount importance as cases continue to rise dramatically across the US. With stockpiles of medical supplies and hospital beds dwindling and the prospect of a vaccine well over a year out, a treatment could help stem the tide at home and abroad.<\/p>\n For more information, check out the full University of Minnesota press release here<\/a> or email <\/a><\/p>\n<\/body><\/html>\n","protected":false},"excerpt":{"rendered":" Exhibiting early promise in treating COVID-19, University of Minnesota Medical School researchers launch the first human trial of hydroxychloroquine.<\/p>\n","protected":false},"author":65186511,"featured_media":1288656,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[414371047],"tags":[201488387,414372326,414372323,414372324,414371327,414372325,195780286,3659],"coauthors":[414371021],"class_list":["post-1288655","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-livebig","tag-btn-livebig-2","tag-clinical-trials","tag-coronavirus","tag-covid-19","tag-healthcare","tag-hydroxychloroquine","tag-livebig-minnesota","tag-medicine"],"acf":[],"yoast_head":"\n